CiloTax StentTM - summitMD.com

More documents

Recommendations

Info

Cilostazol-eluting Stent in a Porcine Coronary Model Anti-restenotic Effect 2.5 2 CES (n=6) BMS (n=5) 1.5 1 0.5 P=0.04 P=0.03 400 µg/18mm stent 0 Intimal area (mm 2 ) Late loss (mm) Tsuchikane E, et al. J Invasive Cardiol 2007;19(3):109
The Ideal Combination? Cilotax TM Stent Dual-Drug DES Potential Synergism with Paclitaxel Cilostazol 1. Anti-platelet effect stent thrombosis ↓ 2. Anti-proliferative effect restenosis ↓
Page 1 and 2: CiloTax Stent TM Dual Drug-eluting
Page 3 and 4: Moving Forward Co-drug Eluting Sten
Page 5 and 6: A Potent Anti-platelet Agent Effect
Page 7: Anti-restenotic Effect DECLARE - Lo
Page 11 and 12: Cilotax Stent TM Polymer & Drugs Po
Page 13 and 14: Safety and Efficacy of the Cilotax
Page 15 and 16: Animal Preparation • Juvenile swi
Page 17 and 18: Analysis • Angiography and IVUS:
Page 19 and 20: Results 3.0 18mm Cilotax BMS 4 week
Page 21 and 22: IVUS Analysis at Follow-Up (n=7) BM
Page 23 and 24: Results BMS (n=3) Cilotax stent (n=
Page 25 and 26: Results Inflammatory Response BMS (
Page 27 and 28: Clinical Study Efficacy and Safety
Page 29 and 30: Objectives • to assess safety and
Page 31 and 32: Study Endpoints • Statistics - a

CiloTax StentTM - summitMD.com

Create successful ePaper yourself

Delete template?

Save as template?